Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Spooked By America’s COVID-19 Vaccine Skepticism, FDA Promises Not To Lower Standards

Plus: Inovio Unveils Phase I Data, Reaction To Remdesivir Price

Executive Summary

The FDA has released detailed guidance to COVID-19 vaccine manufacturers setting out the safety and efficacy standards required, and pledged to not cut corners.

You may also be interested in...



Coronavirus Update: Lower Immune Responses Could See ‘Shake Out’ Of Vaccine Contenders

Leader of London university's vaccine contender hopeful of breakthrough in early 2021, but thinks Oxford's forecast of September overly optimistic.

COVID-19 Vaccine Should Demonstrate At Least 50% Effectiveness, US FDA Says

Guidance on COVID-19 vaccine development and licensure appears to set a precedent in specifying the clinical efficacy rate for a product approval; agency also takes accelerated approval off the table for now and says emergency use authorization may be granted only after safety and efficacy have been demonstrated.

Pfizer CEO Bourla Wants Profit From COVID-19 Vaccine

Several countries already are calling about orders, as the company prepares to begin a Phase III trial of its mRNA coronavirus vaccine candidate.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel